Cancer Research Annual Meeting 2010 Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vonderheide, R. H.
Right arrow Articles by Nadler, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vonderheide, R. H.
Right arrow Articles by Nadler, L. M.
[Cancer Research 61, 8366-8370, December 1, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Equivalent Induction of Telomerase-specific Cytotoxic T Lymphocytes from Tumor-bearing Patients and Healthy Individuals1

Robert H. Vonderheide2,3, Joachim L. Schultze3, Karen S. Anderson, Britta Maecker, Marcus O. Butler, Zhinan Xia, Marcelo J. Kuroda, Michael S. von Bergwelt-Baildon, Michelle M. Bedor, Kara M. Hoar, Deborah R. Schnipper, Mary W. Brooks, Norman L. Letvin, Katherine F. Stephans, Kai W. Wucherpfennig, William C. Hahn and Lee M. Nadler

Departments of Adult Oncology [R. H. V., J. L. S., K. S. A., B. M., M. O. B., Z. X., M. S. v. B-B., M. M. B., K. M. H., D. R. S., K. F. S., W. C. H., L. M. N.] and Cancer Immunology and AIDS [K. W. W.], Dana-Farber Cancer Institute; Department of Medicine, Brigham and Women’s Hospital [R. H. V., J. L. S., K. S. A., M. O. B., W. C. H., L. M. N.]; Department of Medicine, Beth Israel Deaconess Medical Center [M. J. K., N. L. L.]; Department of Medicine, Harvard Medical School [R. H. V., J. L. S., K. S. A., M. O. B., M. J. K., N. L. L., W. C. H., L. M. N.] Boston, Massachusetts 02115; and Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142 [M. W. B., W. C. H.]

Although high frequencies of T lymphocytes specific for certain tumor-associated antigens have been detected in some cancer patients, increasing evidence suggests that these T cells may be functionally defective in vivo and fail to induce meaningful clinical responses. One strategy to overcome this limitation is to target novel antigens that are ignored during the natural antitumor immune response but are nevertheless capable of triggering effector T-cell responses against tumors after optimal presentation by antigen-presenting cells. Here, we show that the telomerase catalytic subunit (hTERT)—a nearly universal tumor antigen identified by epitope deduction rather than from patient immune responses—is immunologically ignored by patients despite progressive tumor burden. Nevertheless, HLA-A2-restricted CTLs against hTERT are equivalently induced ex vivo from patients and healthy individuals and efficiently kill human tumor cell lines and primary tumors. Thus, telomerase-specific T cells from cancer patients are spared functional inactivation because of immunological ignorance. These findings support clinical efforts to target the hTERT as a tumor antigen with broad therapeutic potential.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
E. Kondo, B. Maecker, M. R. Weihrauch, C. Wickenhauser, W. Zeng, L. M. Nadler, J. L. Schultze, and M. S. von Bergwelt-Baildon
Cyclin D1-Specific Cytotoxic T Lymphocytes Are Present in the Repertoire of Cancer Patients: Implications for Cancer Immunotherapy
Clin. Cancer Res., October 15, 2008; 14(20): 6574 - 6579.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. N. Haining, J. Davies, H. Kanzler, L. Drury, T. Brenn, J. Evans, J. Angelosanto, S. Rivoli, K. Russell, S. George, et al.
CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans
Clin. Cancer Res., September 1, 2008; 14(17): 5626 - 5634.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. M. Domchek, A. Recio, R. Mick, C. E. Clark, E. L. Carpenter, K. R. Fox, A. DeMichele, L. M. Schuchter, M. S. Leibowitz, M. H. Wexler, et al.
Telomerase-Specific T-Cell Immunity in Breast Cancer: Effect of Vaccination on Tumor Immunosurveillance
Cancer Res., November 1, 2007; 67(21): 10546 - 10555.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Parmiani, V. Russo, A. Marrari, G. Cutolo, C. Casati, L. Pilla, C. Maccalli, L. Rivoltini, and C. Castelli
Universal and Stemness-Related Tumor Antigens: Potential Use in Cancer Immunotherapy
Clin. Cancer Res., October 1, 2007; 13(19): 5675 - 5679.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Adotevi, K. Mollier, C. Neuveut, S. Cardinaud, E. Boulanger, B. Mignen, W.-H. Fridman, M. Zanetti, P. Charneau, E. Tartour, et al.
Immunogenic HLA-B*0702-Restricted Epitopes Derived from Human Telomerase Reverse Transcriptase That Elicit Antitumor Cytotoxic T-Cell Responses.
Clin. Cancer Res., May 15, 2006; 12(10): 3158 - 3167.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Filaci, M. Fravega, M. Setti, P. Traverso, E. Millo, D. Fenoglio, S. Negrini, F. Ferrera, A. Romagnoli, M. Basso, et al.
Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer
Blood, February 15, 2006; 107(4): 1505 - 1512.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. B. Rew, K. Peggs, I. Sanjuan, A. R. Pizzey, Y. Koishihara, S. Kawai, M. Kosaka, S. Ozaki, B. Chain, and K. L. Yong
Generation of Potent Antitumor CTL from Patients with Multiple Myeloma Directed against HM1.24
Clin. Cancer Res., May 1, 2005; 11(9): 3377 - 3384.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. M. Coughlin, B. A. Vance, S. A. Grupp, and R. H. Vonderheide
RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy
Blood, March 15, 2004; 103(6): 2046 - 2054.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. H. Vonderheide, S. M. Domchek, J. L. Schultze, D. J. George, K. M. Hoar, D.-Y. Chen, K. F. Stephans, K. Masutomi, M. Loda, Z. Xia, et al.
Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes
Clin. Cancer Res., February 1, 2004; 10(3): 828 - 839.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Maecker, D. H. Sherr, R. H. Vonderheide, M. S. von Bergwelt-Baildon, N. Hirano, K. S. Anderson, Z. Xia, M. O. Butler, K. W. Wucherpfennig, C. O'Hara, et al.
The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells
Blood, November 1, 2003; 102(9): 3287 - 3294.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. C. Hahn
Role of Telomeres and Telomerase in the Pathogenesis of Human Cancer
J. Clin. Oncol., May 15, 2003; 21(10): 2034 - 2043.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Hernandez, F. Garcia-Pons, Y. C. Lone, H. Firat, J. D. Schmidt, P. Langlade-Demoyen, and M. Zanetti
Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells
PNAS, September 17, 2002; 99(19): 12275 - 12280.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.